Floatz logo

TIL

Treatment Side Effects

Shanghai Juncell TherapeuticsCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Treatment Side Effects cohort.

Asset / SponsorPhaseRating
Velpatasvir
Alexandria University
Phase 4BB
AUTOLOGOUS CONDITIONED PLASMA
Star Spine and Sport
Phase 4BB
Sofosbuvir
Alexandria University
Phase 4BB
Paliperidone Palmitate 3-Month Formulation
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Phase 4BB
NEPENTHE
Hopital Lariboisière
Phase 4BB

View all 37 →

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →